Xultophy

Drug List

Xultophy

Drug Name

Xultophy (Insulin degludec and liraglutide)

Manufactured By

Novo Nordisk Pharmaceuticals, Inc.

Drug Savings

Nationwide Prescription Connection (NPC) is an experienced advocacy service that helps connect patients to manufacturer provided free and discount programs. We can help the uninsured, under insured, those in the Medicare gap also known as the "doughnut hole", or even those needing help with expensive co-pays.  Our web site makes it easy for you to enter the medications you are taking, along with some basic patient information, and then finds the program that is right for you.

Nationwide Prescription Connection (NPC) is an experienced advocacy service that helps connect patients to manufacturer provided free and discount programs. We can help the uninsured, under insured, those in the Medicare gap also known as the "doughnut hole", or even those needing help with expensive co-pays.  Our web site makes it easy for you to enter the medications you are taking, along with some basic patient information, and then finds the program that is right for you.

Treats Disease/Condition

Uses

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).

How To Use

• Read the Instructions for Use that comes with XULTOPHY® 100/3.6. • Use XULTOPHY® 100/3.6 exactly as your healthcare provider tells you to. • Do not change your dosing schedule without first talking to your healthcare provider. The dose counter on your XULTOPHY® 100/3.6 pen shows the number of units of XULTOPHY® 100/3.6 to be injected • Your healthcare provider should show you how to use XULTOPHY® 100/3.6 before you use it for the first time. • XULTOPHY® 100/3.6 is injected under the skin (subcutaneously) of your thigh, upper arm or stomach (abdomen)

Side Effects

The most common adverse reactions, reported in ≥5% of patients treated with Xultophy® 100/3.6 are nasopharyngitis, headache, nausea, diarrhea, increased lipase and upper respiratory tract infection.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine). Liraglutide-containing products, including Xultophy® 100/3.6, cause a delay of gastric emptying, and thereby have the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with liraglutide-containing products.

In Case of Overdose

Overdose Due to Medication Errors: Instruct patients to check the label before each injection since accidental mix-ups with insulin containing products can occur. Administration of more than 50 units of Xultophy® 100/3.6 daily or use with other GLP-1 receptor agonists can result in overdose.

In Case of Missed Dose

• If you miss a dose of XULTOPHY® 100/3.6, resume your 1 time daily dosing schedule at the next scheduled dose. Do not take 2 doses at the same time or increase your dose to make up for the missed dose. If you miss more than 3 days of XULTOPHY® 100/3.6, call your healthcare provider for further instructions about taking XULTOPHY® 100/3.6 at the right dose and to help lower your chance of having an upset stomach. • Do not mix XULTOPHY® 100/3.6 with

Storage